Company Description
OXiGENE starves cancer to death. The company's lead drug candidate, Zybrestat, works by disrupting the functioning of blood vessels that deliver...
Key OXiGENE Financials
| Company Type | Public - NASDAQ (GM): OXGN Main Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2007 Sales (mil.) | $0.0 |
| 2005 Employees | 26 |
More OXiGENE Financials (11 pages)
Competition
Competitive Landscape for Chemicals
Demand is driven by the health of the US economy because chemicals are used to make a wide variety of industrial and consumer products. The profitability of individual companies is closely tied to...
Read more about OXiGENE's competition across multiple industries
Top OXiGENE Competitors
Sponsored Links
The Business DirectoryOXiGENE Executives
| Title | Name & Bio | Contact |
|---|---|---|
| Chairman | Joel Tomas Citron | Network | E-mail |
| President, CEO, and Director | Richard Chin | Network | E-mail |
| VP and CFO | James B. Murphy | Network | E-mail |
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Current OXiGENE News
- OXiGENE, Inc. (OXGN) Corporate Event Announcement Notice [Wall Street Horizon] (04 Aug 2008 21:05:00 EDT)
- FirstAlert: 1-3 P.M. Investrend / Bestcalls [InvesTrend] (03 Aug 2008 00:01:00 EDT)
Sponsored Opportunity










